Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Pre-Mkt 06-15 05:43:21 EDT

59.77

+0.68

+1.14%

High61.17	Low59.06	Vol154.41K
Open59.41	D1 Closing59.10	Amplitude3.57%
Mkt Cap399.42M	Tradable Cap294.76M	Total Shares6.68M
T/O9.30M	T/O Rate3.13%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":59.77,"timestamp":1781294400000,"preClose":59.095,"halted":0,"volume":154406,"delay":0,"changeRate":0.011422286149420497,"floatShares":4931541,"shares":6682584,"eps":-1.921609,"marketStatus":"Pre-Mkt","change":0.675,"latestTime":"06-15 05:43:21 EDT","open":59.41,"high":61.17,"low":59.06,"amount":9297811,"amplitude":0.035705,"askPrice":64,"askSize":97,"bidPrice":52,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.921609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781530200000},"marketStatusCode":1,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":59.77,"postHourTrading":{"tag":"盘后","latestPrice":59.77,"preClose":59.77,"latestTime":"16:10 EDT","volume":10,"amount":597.7,"timestamp":1781295004983,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2886345843656781},"requestUrl":"/m/hq/s/MNPR","defaultTab":"news","newsList":[{"id":"2640910720","title":"Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910720?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:58","pubTimestamp":1780401520,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $101.00. According to TipRanks...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640633589","title":"Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Gossamer Bio (GOSS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640633589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640633589?lang=en_us&edition=fundamental","pubTime":"2026-06-01 23:30","pubTimestamp":1780327821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monopar Therapeutics Inc (MNPR), Gossamer Bio (GOSS)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-gossamer-bio-goss-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-gossamer-bio-goss-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4139","BK4505","GOSS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640204950","title":"Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640204950","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640204950?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:26","pubTimestamp":1780323968,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $103.00. Messe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640441955","title":"Monopar presents Phase 2 data showing ALXN1840 stabilizes liver disease in Wilson patients at EASL 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640441955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640441955?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:04","pubTimestamp":1780311881,"startTime":"0","endTime":"0","summary":"Monopar highlighted Phase 2 ALXN1840 data already presented at EASL 2026 in treatment-experienced Wilson disease patients.The 48-week study showed liver disease generally stabilized, with some patients showing improvement on biopsy assessments.Patients also showed improvement in neurological symptoms, with gains in overall clinical status and reported quality of life.Safety was broadly consistent with tolerability expectations, with most side effects described as nonserious.The readout supports ALXN1840’s positioning for Wilson disease patients inadequately served by current standard therapies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL1HyH56:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","LU2210150020.SGD","NDAQ","LU2210149790.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4139","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","MNPR","IE00B64PRP62.GBP","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867567","title":"Monopar says Phase 2 trial shows ALXN1840 improves copper balance in Wilson disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867567","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867567?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:27","pubTimestamp":1779226034,"startTime":"0","endTime":"0","summary":"Monopar flagged a newly published peer-reviewed Phase 2 open-label study on ALXN1840 in Wilson disease, with results already presented in the journal article.The trial showed the drug rapidly improved copper control versus patients’ pre-treatment baseline, supporting its potential to reduce harmful copper build-up over time.Investigators reported the effect was sustained during the study period, with the improvement driven by greater elimination of copper through the digestive tract.The treatment was generally well tolerated, with no serious adverse events reported.Monopar framed the findings as supportive of prior Phase 3 evidence that ALXN1840 can outperform current standard treatments even in long-treated patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLccq9Vk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076306","title":"Analysts’ Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076306?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:00","pubTimestamp":1779109252,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monopar Therapeutics Inc (MNPR), Voyager Therapeutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-monopar-therapeutics-inc-mnpr-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-monopar-therapeutics-inc-mnpr-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4139","BK4585","BK4581","BK4588","BK4137","HCSG","LABU","VYGR","XBI","MNPR","LU0128526141.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076802","title":"Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076802","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076802?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:00","pubTimestamp":1779109233,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $59.27. According to TipRan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085586","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085586?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:40","pubTimestamp":1778841616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zenas BioPharma, Inc. (ZBIO), Monopar Therapeutics I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0128526141.USD","LU0029874061.USD","MNPR","XBI","BK4585","LABU","BK4112","ZBIO","BLSG","BK4581","BLSX","BK4137","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635046729","title":"Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635046729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635046729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:10","pubTimestamp":1778793005,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics (AQST) and Monopar Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-aquestive-therapeutics-aqst-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-aquestive-therapeutics-aqst-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AQST","LU0029874061.USD","BK4581","MNPR","BLSG","BK4007","BLSX","LABU","BK4139","BK4585","BK4112","BK4137","XBI","LU0128526141.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635740576","title":"Monopar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635740576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635740576?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:02","pubTimestamp":1778785339,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMonopar Therapeutics Inc MNPR.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635474789","title":"Monopar Therapeutics Q1 EPS $(0.46) Beats $(0.83) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635474789","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635474789?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:03","pubTimestamp":1778781822,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Q1 EPS $(0.46) Beats $(0.83) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/MNPR","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742004","title":"Monopar net loss widens to $3.89 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742004","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742004?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:01","pubTimestamp":1778781704,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics posted a net loss of USD 3.89 million for Q1 ended March 31, 2026, widening from USD 2.62 million a year earlier.Operating loss widened to USD 5.23 million, while total operating expenses climbed to USD 5.23 million.Research and development expenses more than doubled to USD 3.49 million, while general and administrative costs rose 10.11% to USD 1.74 million.Interest income jumped to USD 1.33 million, reflecting higher balances following net proceeds of about USD 91.9 million from a September 2025 capital raise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL8H6f1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742726","title":"Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742726?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:00","pubTimestamp":1778781600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAHDDTF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742013","title":"Monopar Therapeutics Inc - on Track to Submit Nda to FDA in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742013?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:00","pubTimestamp":1778781600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAHDDTF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468387","title":"Monopar Therapeutics Inc  expected to post a loss of 84 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468387","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468387?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:29","pubTimestamp":1778254192,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc  expected to post a loss of84cents a share - Earnings Preview Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632665904","title":"Monopar Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632665904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632665904?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579558,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics will hold its annual stockholders meeting in Wilmette, Illinois on June 22, 2026.Shareholders will vote on election of six directors, including director nominee Nicole Sweeny.Advisory vote on named executive officer compensation is scheduled for consideration.Ballot also includes approval of Monopar 2026 Stock Incentive Plan, which would add 600,000 new shares to equity plan capacity.Meeting agenda includes ratification of BPM LLP as independent registered public accounting firm for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3H0KSs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603200","title":"Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603200?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:40","pubTimestamp":1776778846,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monopar-therapeutics-inc-mnpr-clearpoint-neuro-clpt-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monopar-therapeutics-inc-mnpr-clearpoint-neuro-clpt-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4139","CG","IE00B64PRP62.GBP","XBI","BK4082","CLPT","XLV","LU0029874061.USD","MNPR","BK4588","LABU","LU0128526141.USD","BK4585","IE00BGHQF748.EUR","CGON","HCSG","BK4137","IE00B3QW5Z07.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603809","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603809?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:00","pubTimestamp":1776769222,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-compass-pathways-cmps-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-compass-pathways-cmps-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","LU0029874061.USD","BK4588","XBI","XLV","WHWK","HCSG","BK4585","LABU","MNPR","LU0128526141.USD","BK4581","BK4137","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628792282","title":"Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840","url":"https://stock-news.laohu8.com/highlight/detail?id=2628792282","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628792282?lang=en_us&edition=fundamental","pubTime":"2026-04-20 08:50","pubTimestamp":1776646245,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 showing greater neurologic benefi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monopar-announces-new-analyses-from-phase-3-focus-trial-of-alxn1840-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monopar-announces-new-analyses-from-phase-3-focus-trial-of-alxn1840-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628579182","title":"Monopar says Phase 3 trial shows ALXN1840 beats standard care in neurologic Wilson disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2628579182","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628579182?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:00","pubTimestamp":1776639620,"startTime":"0","endTime":"0","summary":"Monopar reported new Phase 3 FoCus trial analyses showing ALXN1840 delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.Results were presented at American Academy of Neurology Annual Meeting 2026 in a late-breaker oral and poster session.Data showed more patients improved and fewer worsened on ALXN1840 versus standard of care through Week 48.Long-term follow-up indicated neurologic benefit increased on continued treatment and held up for about 3 years.Monopar kept plan for a mid-2026 FDA New Drug Application submission for ALXN1840.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL4Ng4pB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BK4112","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","MNPR","SG9999014021.USD","NDAQ","BK4585","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0272},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.1988},{"period":"1year","weight":0.7673},{"period":"ytd","weight":-0.0847}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.22612},{"month":2,"riseRate":0.285714,"avgChangeRate":0.090755},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.182533},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.03289},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.037743},{"month":6,"riseRate":0.571429,"avgChangeRate":0.027236},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.047687},{"month":8,"riseRate":0,"avgChangeRate":-0.159034},{"month":9,"riseRate":0.333333,"avgChangeRate":0.484161},{"month":10,"riseRate":0.5,"avgChangeRate":0.223985},{"month":11,"riseRate":0.666667,"avgChangeRate":0.047001},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.031256}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}